View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jacob Mekhael
  • Jacob Mekhael

Hyloris FY25 results hold no major surprises

Hyloris reported FY25 results with a cash position of € 13.8m (YE24: € 23.6m), and revenue of € 7.2m (FY24: € 8.5m), driven by increased royalties but offset by lower milestone payments. Hyloris is yet to receive income related to commercialisation of Maxigesic IV in the US as the launch has been paused and restarted. The company did not provide specific cash runway guidance, but believes it has funding for development and strategic growth. € 6 TP and Hold maintained.

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Thomas Couvreur
  • Wim Hoste
Jacob Mekhael
  • Jacob Mekhael

Galapagos Advanced discussions with Gilead on potential collaboration

Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead are in advanced partnership discussions. Economically, Galapagos would effectively co-finance Gilead's acquisition and early-stage development of gamgertamig in return for royalties on net sales (20-23%) and freedom to go up to $500m (previously $150m) in the amended OLCA. In our view, t...

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Livio Luyten
  • Wim Hoste
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Galapagos and Gilead in Advanced Discussions to Collaborate on Advanci...

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities   Mechelen, Belgium; March 23, 2026, 23:02 CE...

 PRESS RELEASE

Galapagos en Gilead in vergevorderde gesprekken over samenwerking om e...

Galapagos en Gilead in vergevorderde gesprekken over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen Galapagos is van plan een strategische samenwerking aan te gaan met Gilead, na de overname van Ouro Medicines door Gilead De nieuwe partnerstructuur zou aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos opleveren Na deze potentiële transactie zal de Vennootschap het grootste deel van haar kapitaal beschikbaar blijven houden voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocat...

 PRESS RELEASE

Disclosure of a transparency notification from Aberdeen Group plc

Disclosure of a transparency notification from Aberdeen Group plc Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Aberdeen Group plc, dated 16 March 2026. Notification from Aberdeen Group plc On 19 March 2026, Fagron received a transparency notification from Aberdeen Group plc, informing the Company that its shareholding has...

 PRESS RELEASE

Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc

Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 20 maart 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, gedateerd op 16 maart 2026. Kennisgeving van Aberdeen Group plc Op 19 maart 2026 ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, waarin aan...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Thibault Leneeuw
  • Thomas Couvreur
Thibault Leneeuw
  • Thibault Leneeuw

Fagron A Clear Path for sustained Double Digit REBITDA Growth

Our analysis of U.S. compounding capacity and utilization shows that North America can sustain double-digit organic growth, driving our 7.4% organic revenue CAGR (25–30) for the group. We expect strong REBITDA growth in 2026, and margin decrease due to acquisitions. Long-term margin upside is well supported by the new U.S. facilities and improved efficiency through centralized manufacturing and vertical integration in LatAm. The market continues to undervalue Fagron by focusing too heavily on ma...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch